Gemfibrozil increases apolipoprotein A-I and cholesterol concentrations in human peripheral lymph

Area of Science:

• Biochemistry
• Lipid Metabolism
• Pharmacology

Background:

• Hyperlipidemia is a major risk factor for cardiovascular disease.
• Very low-density lipoproteins (VLDL) play a key role in triglyceride transport.
• Gemfibrozil is a lipid-lowering drug known to affect VLDL catabolism.

Purpose of the Study:

• To investigate the effects of gemfibrozil on peripheral lymph lipoproteins.
• To explore the relationship between VLDL catabolism and apolipoprotein A-I (apo A-I) and cholesterol levels in lymph.

Main Methods:

• Studied four hyperlipidaemic men before and after 6 weeks of gemfibrozil treatment.
• Analyzed plasma and peripheral lymph triglyceride, cholesterol, and apo A-I concentrations.
• Compared changes with four untreated control subjects.

Main Results:

• Gemfibrozil significantly decreased plasma triglycerides (mean 45%).
• Lymph apo A-I concentration increased significantly (mean 66%), and lymph cholesterol increased (mean 59%).
• Plasma apo A-I and total cholesterol showed non-significant changes.

Conclusions:

• Gemfibrozil treatment enhances apo A-I transfer to lymph, potentially facilitating cholesterol efflux.
• VLDL lipolysis may increase interstitial apo A-I, promoting cellular cholesterol removal.
• Findings support a novel pathway in reverse cholesterol transport.